Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders – Fitusiran Achieves Median Estimated Annualized Bleeding Rate of Zero in Patients without Inhibitors – – In Initial Low Dose Cohort of Patients with Inhibitors, Fitusiran Achieves Antithrombin Lowering, Increased Thrombin Generation, and Preliminary Evidence for Reduced Bleeding – – Fitusiran Administration Generally Well Tolerated in Hemophilia Patients with and without Inhibitors – – Company Updates Guidance for Phase 3, and Now Plans to Start Studies in Early 2017 – –...
↧